AU2015204597B2 - Compositions and methods for treatment of abnormal cell growth - Google Patents

Compositions and methods for treatment of abnormal cell growth Download PDF

Info

Publication number
AU2015204597B2
AU2015204597B2 AU2015204597A AU2015204597A AU2015204597B2 AU 2015204597 B2 AU2015204597 B2 AU 2015204597B2 AU 2015204597 A AU2015204597 A AU 2015204597A AU 2015204597 A AU2015204597 A AU 2015204597A AU 2015204597 B2 AU2015204597 B2 AU 2015204597B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
composition
acceptable salt
pharmaceutical composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015204597A
Other languages
English (en)
Other versions
AU2015204597A1 (en
Inventor
Paul Okwabi Nkansah
Mahesh Padval
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Verastem Inc
Original Assignee
Pfizer Inc
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc, Verastem Inc filed Critical Pfizer Inc
Publication of AU2015204597A1 publication Critical patent/AU2015204597A1/en
Assigned to PFIZER INC., VERASTEM, INC. reassignment PFIZER INC. Amend patent request/document other than specification (104) Assignors: PFIZER, INC., VERASTEM, INC.
Application granted granted Critical
Publication of AU2015204597B2 publication Critical patent/AU2015204597B2/en
Priority to AU2020210153A priority Critical patent/AU2020210153B2/en
Priority to AU2022256144A priority patent/AU2022256144B2/en
Priority to AU2025204843A priority patent/AU2025204843A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2015204597A 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth Active AU2015204597B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020210153A AU2020210153B2 (en) 2014-01-09 2020-07-27 Compositions and methods for treatment of abnormal cell growth
AU2022256144A AU2022256144B2 (en) 2014-01-09 2022-10-19 Compositions and methods for treatment of abnormal cell growth
AU2025204843A AU2025204843A1 (en) 2014-01-09 2025-06-26 Compositions and methods for treatment of abnormal cell growth

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
US61/925,467 2014-01-09
PCT/US2015/010810 WO2015106096A1 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020210153A Division AU2020210153B2 (en) 2014-01-09 2020-07-27 Compositions and methods for treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
AU2015204597A1 AU2015204597A1 (en) 2016-07-21
AU2015204597B2 true AU2015204597B2 (en) 2020-04-30

Family

ID=52434976

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015204597A Active AU2015204597B2 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth
AU2020210153A Active AU2020210153B2 (en) 2014-01-09 2020-07-27 Compositions and methods for treatment of abnormal cell growth
AU2022256144A Active AU2022256144B2 (en) 2014-01-09 2022-10-19 Compositions and methods for treatment of abnormal cell growth
AU2025204843A Pending AU2025204843A1 (en) 2014-01-09 2025-06-26 Compositions and methods for treatment of abnormal cell growth

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020210153A Active AU2020210153B2 (en) 2014-01-09 2020-07-27 Compositions and methods for treatment of abnormal cell growth
AU2022256144A Active AU2022256144B2 (en) 2014-01-09 2022-10-19 Compositions and methods for treatment of abnormal cell growth
AU2025204843A Pending AU2025204843A1 (en) 2014-01-09 2025-06-26 Compositions and methods for treatment of abnormal cell growth

Country Status (15)

Country Link
US (3) US20150190346A1 (enExample)
EP (2) EP3091981B1 (enExample)
JP (5) JP6647204B2 (enExample)
KR (3) KR20220130251A (enExample)
CN (3) CN119868364A (enExample)
AU (4) AU2015204597B2 (enExample)
BR (1) BR112016016021B1 (enExample)
CA (1) CA2936283C (enExample)
DK (1) DK3091981T3 (enExample)
ES (1) ES2870562T3 (enExample)
IL (2) IL246667B (enExample)
MX (2) MX384259B (enExample)
NZ (2) NZ760233A (enExample)
SG (2) SG11201605588YA (enExample)
WO (1) WO2015106096A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3097594A1 (en) * 2018-05-15 2019-11-21 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pharmaceutical composition comprising small molecule egfr inhibitor and preparation method therefor
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
MX2022010811A (es) * 2020-03-27 2022-09-27 Pfizer Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo.
IL297020A (en) * 2020-04-24 2022-12-01 Dr Falk Pharma Gmbh A systemic preparation of a pyridonone derivative related to tg2
HRP20231072T1 (hr) 2020-04-24 2023-12-22 Dr. Falk Pharma Gmbh Sustavna formulacija derivata piridinona za celijakiju
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008129380A1 (en) * 2007-04-18 2008-10-30 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
CA2534371A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
RS56894B1 (sr) * 2008-08-13 2018-04-30 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
JP2013536231A (ja) * 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
WO2012122279A1 (en) * 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
EA201890161A1 (ru) * 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008129380A1 (en) * 2007-04-18 2008-10-30 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JAMES C. DINUNZIO ET AL, "Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol Dispersing", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, (2010-09-01), vol. 36, no. 9, pages 1064 - 1078 *
R N. Shamma et al, "Soluplus: A novel polymeric solubilizer for optimization of Carvedilol solid dispersion: Formulation", Powder Technology, (2013), vol. 237, page 406-414 *
Shu Li et al., "Enhanced Bioavailability of a Poorly Water-Soluble Weakly Basic Compound Using a Combination Approach of Solubilization Agents and Precipitation Inhibitors: A Case Study", Molecular Pharmaceutics *
WILLIAM CURATOLO ET AL, "Utility of Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and Maintenance of Drug Supersaturation in the GI Milieu", PHARMACEUTICAL RESEARCH, (2009-03-10), vol. 26, no. 6,pages 1419 - 1431 *
Y. KANG ET AL, "Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer", JNCI JOURNAL OF THE NATIONAL CANCER INSTITUTE, (2013-10-02), vol. 105, no. 19,pages 1485 - 1495 *

Also Published As

Publication number Publication date
IL292054A (en) 2022-06-01
WO2015106096A1 (en) 2015-07-16
IL246667A0 (en) 2016-08-31
EP3091981B1 (en) 2021-03-10
JP2023065568A (ja) 2023-05-12
AU2025204843A1 (en) 2025-07-17
DK3091981T3 (da) 2021-05-31
US20150190346A1 (en) 2015-07-09
ES2870562T3 (es) 2021-10-27
AU2020210153A1 (en) 2020-08-13
IL246667B (en) 2022-05-01
JP2025084892A (ja) 2025-06-03
JP2020007355A (ja) 2020-01-16
US20230104303A1 (en) 2023-04-06
CA2936283A1 (en) 2015-07-16
BR112016016021A2 (pt) 2017-09-19
AU2015204597A1 (en) 2016-07-21
US20200038331A1 (en) 2020-02-06
SG10201805890QA (en) 2018-08-30
AU2022256144A1 (en) 2022-11-24
KR20160104725A (ko) 2016-09-05
BR112016016021A8 (pt) 2018-04-17
MX384259B (es) 2025-03-14
KR102444494B1 (ko) 2022-09-20
NZ721934A (en) 2022-04-29
MX2016009056A (es) 2017-01-23
JP2017502062A (ja) 2017-01-19
JP6647204B2 (ja) 2020-02-14
NZ760233A (en) 2022-04-29
KR20220130251A (ko) 2022-09-26
EP3900726A1 (en) 2021-10-27
CN119868364A (zh) 2025-04-25
CA2936283C (en) 2023-02-28
AU2020210153B2 (en) 2022-07-21
CN115708827A (zh) 2023-02-24
BR112016016021B1 (pt) 2023-01-10
EP3091981A1 (en) 2016-11-16
JP2022001587A (ja) 2022-01-06
KR20240159639A (ko) 2024-11-05
MX2021008225A (es) 2021-08-11
CN106102744A (zh) 2016-11-09
AU2022256144B2 (en) 2025-04-03
SG11201605588YA (en) 2016-08-30

Similar Documents

Publication Publication Date Title
AU2022256144B2 (en) Compositions and methods for treatment of abnormal cell growth
JP5658679B2 (ja) ベンダムスチンの固体投与剤
TW202432128A (zh) （Ｒ）－１－（１－丙烯醯基哌啶－３－基）－４－胺基－３－（４－苯氧基苯基）－１Ｈ－咪唑並［４，５－ｃ］吡啶－２（３Ｈ）－酮之藥品調配物
EP3052130B1 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
KR101587140B1 (ko) 위장관 질환 치료용 모사프리드 구연산염 미니정제 함유 서방성 캡슐 제제 및 이의 제조 방법
HK40062771A (en) Compositions and methods for treatment of abnormal cell growth
CN105311635A (zh) 可调控释放度的高载药量的医药组合物及其制备方法
CN119365195A (zh) 含有匹米替比的医药组合物
HK1230956B (en) Compositions and methods for treatment of abnormal cell growth
CN115835859A (zh) 包括西他列汀和达格列净的复合制剂以及其制备方法
HK1230942A1 (en) Compositions and methods for treatment of abnormal cell growth
EP4168011B1 (en) Oral formulations and uses thereof
RU2586290C1 (ru) Твердая лекарственная форма прокарбазина немедленного высвобождения и способ ее получения
KR20260022394A (ko) 에스트로겐 수용체 분해제의 고형 경구제
CN115837013A (zh) 枸橼酸爱地那非胶囊剂及其制备方法和用途
HK1242993A1 (en) A pharmaceutical composition in a solid dosage form suitable for oral administration

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: PFIZER INC.

Free format text: FORMER NAME(S): VERASTEM, INC.; PFIZER, INC.

Owner name: VERASTEM, INC.

Free format text: FORMER NAME(S): VERASTEM, INC.; PFIZER, INC.

FGA Letters patent sealed or granted (standard patent)